Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial
Ciara Louise Freeman(Moffitt Cancer Center), Matthew J. Frigault(Harvard University), Tim Welliver, Carolyn Jackson, Enrique Granados, Cindy Varga, Natalie S. Callander(University of Wisconsin–Madison), Carolina Schinke(University of Arkansas for Medical Sciences), Abhinav Deol(Wayne State University), Noa Biran(Hackensack University Medical Center), Douglas W. Sborov(University of Utah), Mehmet H. Kocoglu(University of Maryland, Baltimore), Gurbakhash Kaur(The University of Texas Southwestern Medical Center), Andrzej Jakubowiak(University of Chicago Medical Center), Krina K. Patel(University of Vermont), Abraham S. Kanate(HonorHealth), Myrna Nahas, Adam S. Sperling(Dana-Farber Cancer Institute), Richard T. Maziarz(Oregon Health & Science University), Rebecca J. Chan(CardioDx (United States)), Christopher R. Heery(National Cancer Institute), Binod Dhakal(Medical College of Wisconsin), Melhem Solh(Johns Hopkins Hospital), Ana Kostić(Agriculture and Agri-Food Canada), Kamalika Banerjee(XCell Science (United States))
Cited by 20
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
|New England Journal of Medicine|2020|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k